Larimar Therapeutics Inc. (NASDAQ: LRMR) is trading lower on Monday after the company released data from the ongoing ...
GlobalData on MSN
Trials to watch: Three major catalysts in Alzheimer’s disease
While Lilly and Eisai/Biogen have validated the amyloid theory, there is an unmet need for drugs with alternative mechanisms ...
In 4 completed studies and the ongoing OL study, 65 participants received at least 1 dose of nomlabofusp, including 39 in the ...
The FDA approved a supplemental new drug application for Tremfya for the treatment of children aged 6 years or older with ...
The FDA has approved Johnson & Johnson’s TREMFYA for children aged 6+ weighing at least 40 kg with moderate to severe plaque ...
Amneal submits a BLA for a new Xolair biosimilar, promising affordable treatment options for asthma and allergies, enhancing ...
Larimar Therapeutics (LRMR) announced 25 mg and 50 mg data from the ongoing long-term open label study evaluating daily subcutaneous injections of ...
Roche has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a ...
The FDA in September issued two rejections for spinal muscular atrophy therapies—both linked to manufacturing problems—and ...
Korean biotech company GI Innovation said Monday it has received Fast Track Designation from the US Food and Drug ...
Subcutaneous isatuximab plus bortezomib, lenalidomide, and dexamethasone is effective in transplant-ineligible, newly diagnosed multiple myeloma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback